This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and platinum-based chemotherapy.